Neutrophil gelatinase-associated lipocalin and Fibrinogen-to-albumin ratio are indicators of nephropathy in adult steady state sickle cell disease patients: A multicenter case-control study in Ghana.

- 4 Stephen Twumasi^{1*}, Enoch Odame Anto^{1,2}, Christian Obirikorang³, Richard Kobina Dadzie
- 5 Ephraim⁴, Benedict Sackey^{1,5}, Vivian Paintsil^{6,8}, Richard Owusu Ansah⁷, Alfred Effah³, Allwell
- 6 Adofo Ayirebi¹, Angela Opoku⁶, Godfred Yawson Scott¹, Leslie Osei⁶, Joyce Duku⁹, Emmanuel
- 7 Asafo Adjei⁹, Lilian Antwi Boateng^{1,5*}
- 8 ¹Department of Medical Diagnostics, Faculty of Allied Health Sciences, College of Health
- 9 Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
- 10 ²School of Medical and Health Sciences, Edith Cowan University, Joondalup Drive, Perth,
- 11 Australia
- 12 ³Department of Molecular Medicine, School of Medicine and Dentistry, Kwame Nkrumah
- 13 University of Science and Technology, Kumasi, Ghana
- ¹⁴ ⁴Department of Medical Laboratory Science, University of Cape Coast, Cape-Coast, Ghana
- ¹⁵ Laboratory Department, University Health Services, Kwame Nkrumah University of Science and
- 16 Technology, Kumasi, Ghana
- 17 ⁶Sickle Cell Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana
- ⁷Genomic Laboratory, Faculty of Allied Health Sciences, College of Health Sciences, Kwame
- 19 Nkrumah University of Science and Technology, Kumasi, Ghana
- 20 ⁸Department of Child Health, School of Medical Sciences, Kwame Nkrumah University of
- 21 Science and Technology, Kumasi, Ghana
- ⁹Sickle cell clinic, Kumasi south Hospital, Kumasi, Ghana
- 23 *Corresponding Authors: Stephen Twumasi (<u>stwumasi7116@gmail.com</u>)
- 24 Lilian Antwi Boateng (akosboak@yahoo.com)

25 Abstract

Background: Progressive renal failure is one of the main complications in sickle cell disease.
Neutrophil Gelatinase-Associated Lipocalin (NGAL) is present in gelatinase/tertiary granules of
neutrophils and it is a relatively newly recognized marker of nephropathy. Fibrinogen increases and
albumin decreases in inflammatoy conditions like SCD. This study investigated the diagnostic roles
of NGAL and fibrinogen-to-albumin ratio in steady state adult sickle cell disease patients.

31 **Methods:** In this study, 104 sickle cell disease participants and 51 healthy subjects were analysed.

Participants' information was thoroughly documented using a structured questionnaire and patient case records. To evaluate the hematobiochemical parameters, 5ml of venous blood was drawn from each participant and a clean catch of mid-stream urine was collected from each participant. Subjects with sickle cell disease were further classified as SCD nephropathy and SCD nonnephropathy subjects based on reduced estimated Glomerular Filtration Rate (eGFR) and microalbuminuria.

38 Results: Prevalence of nephropathy was 32.7% among adult steady state SCD patients. Significant 39 high levels of Urine Albumin-to-Creatinine Ratio (UACR), NGAL and fibrinogen-to-albumin ratio (FAR) were seen in SCD patients with nephropathy compared to those without nephropathy 40 (p<0.001). NGAL levels significantly increased along with increased urine albumin-to-creatinine 41 42 ratio (r=0.28, p < 0.005) in both SCD with nephropathy and those without nephropathy. There was a 43 significant negative correlation between creatinine (r=-0.90, p < 0.0005), urea (r=-0.50, p < 0.0005) 44 and eGFR in SCD subjects. Similarly, a significant negative relationship existed between UACR and eGFR (r=-0.34, p<0.0005). Creatinine also had a significant positive correlation with UACR 45 46 (r=0.27, p<0.005 and urea (r=0.56, p<0.0005) in SCD subjects. NGAL was found to be a good 47 predictor of nephropathy in steady state SCD patients with AUC=0.742, p<0.0001 when compared

48 with creatinine and urea with AUC=0.618, p=0.048 and AUC=0.531, p=0.647 respectively. 49 However, FAR could not be used as a predictive marker since it had non-significant poor 50 performance (AUC=0.462, *p*=0.536). 51 **Conclusion:** NGAL as independent marker, is an early predictor of kidney disease as compared to urea and creatinine. Fibrinogen-to-albumin ratio can be used to track nephropathy treatment in 52 53 steady state sickle cell disease patients since it is elevated in those with sickle cell nephropathy compared to healthy individuals. These two markers can be added to the available array of test in 54 the management of nephropathy among steady SCD patients. 55 Keywords 56 Sickle cell disease, Sickle cell nephropathy, Serum neutrophil gelatinase- associated lipocalin, 57 Fibrinogen-to-albumin ratio, microalbuminuria 58

59

60 Introduction

61 Renal injury is a common consequence of sickle cell disease (SCD) caused by long-term anemia and disrupted circulation through the medullar capillaries (1). Between 5% and 18% of sickle cell 62 63 disease patients get renal failure (2). Renal failure affects 4-21% of adult SCD patients due to 64 nephropathy in the United States (3). In Ghana, 39.6% of SCD children with nephropathy were 65 found to have CKD based on decreased eGFR (4). According to a study conducted in Ghana by Ephraim et al., (2015), the prevalence of CKD in the overall SCD population was found to be 39.2%, 66 with adults having a prevalence of 68.4% and children having a prevalence of 31.6% (5). The 67 68 detection of increasing renal impairment using conventional markers such as serum creatinine levels (Cr), or creatinine clearance (Ccr) and urea are frequently deceptive. The serum creatinine, the 69 70 primary clinical tool for measuring renal function is insensitive for the detection of moderate

alterations in renal function and is affected by factors unrelated to renal activity, such as age, gender, race, and lean muscle mass (6). The equations to estimate glomerular filtration rate do not present a good correlation with laboratory measurements (7). The conventional renal function tests such as serum creatinine, urea and glomerular filtration rate show abnormal results in SCD only when there is extensive renal damage (8). There is a growing need to develop more sensitive markers for the early detection of renal dysfunction in SCD patients since derangement of the conventional markers would be late indicators of irreversible kidney damage.

Neutrophil Gelatinase-Associated Lipocalin (NGAL) is present in tertiary granules of activated 78 79 neutrophils. Kidney tubular cells may produce NGAL in response to various injuries. It is a relatively newly recognized marker of nephropathy. NGAL was suggested to be a biomarker of acute kidney 80 injury (AKI) even in the setting of chronic kidney disease and has a strong association with 81 albuminuria(9). Following ischemia and acute kidney injury, NGAL is one of the earliest substances 82 that are released into the urine. However, there are limited studies of NGAL in SCD as a marker of 83 84 renal tubular damage and SCN(10). In cancer studies, the fibrinogen-to-albumin ratio (FAR) was a more significant predictive factor than each indicator itself (11). The purpose of this study is to see 85 if NGAL and FAR could be used as indicators of renal impairment in sickle cell disease patients. 86

87 Materials and Methods

88 Study design, duration and study setting

The present study utilized a prospective case-control design and it was conducted at Komfo Anokye Teaching Hospital (KATH), Kumasi South Government Hospital and Suntreso Government Hospital from November 25, 2023 to March 31, 2024. The KATH is located at Bantama, Kumasi, Ashanti Region, Ghana. It is the sole tertiary healthcare facility in the Ashanti Region and the second-largest hospital in Ghana. Kumasi South Hospital is located in Atonsu Agogo and Suntreso

Government Hospital is located in Suntreso. These facilities are situated in the Kumasi Metropolis in the Ashanti Region of Ghana. They are a 24- hour working health facilities that boast of services like laboratory, radiology, obstetrics and gynaecology, surgery, paediatrics, internal medicine and emergency among others. They also have a sickle cell clinic from where SCD participants were recruited for the study.

99 Ethical Clearance and Informed Consent

The Komfo Anokye Teaching Hospital's (KATH IRB/AP/175/23) and Kwame Nkrumah University of Science and Technology's (CHRPE/AP/1037/23) committees on human research and publication ethics approved the study. Once the study participants had received a thorough explanation of the study's objectives, advantages, risks, and right to withdraw at any time in both English and the local dialect (primarily Twi), their written consent was requested.

105 Study population and selection of participants

According to this study, the participants classified as cases comprised individuals who have been medically diagnosed with SCD. The cases were further categorized into sickle cell nephropathy and sickle cell non-nephropathy subjects based on reduced estimated Glomerular Filtration Rate (eGFR) and microalbuminuria. The individuals classified as controls on the other hand, were characterized by their overall good health and absence of sickle cell disease and nephropathy.

The aim of the study was explained to the study participants. Then, the processes involved in the study, including blood and urine sampling, data collection and laboratory assays were explained to the eligible participants with the help of a clinician.

114 We then purposively recruited a total of 104 SCD patients and 80 healthy individuals, of which 51

115 healthy individuals were without nephropathy and were analysed. The SCD patients were registered

116 with the sickle cell clinic at the Komfo Anokye Teaching Hospital and Kumasi South Government

Hospital. They reported at the clinic for a review as and when directed by their physician. Owing to their clinical history, physicians in both hospitals assessed the SCD patients and declared them fit for the study before they were recruited. Healthy controls were blood donors from the blood bank units of Suntreso Government hospital and Komfo Anokye Teaching Hospital.

SCD patients who are above eighteen (18) years in a steady state for at least one month, and are 121 122 without history of diabetes mellitus, arterial hypertension, neoplastic, cardiovascular, renal, lung or 123 endocrine disease were eligible for this study. Also, SCD participants who had symptoms suggestive 124 of sickle cell pain crisis, acute sickness (fever or required referral to an urgent care facility), clinically suspected urinary tract infection and extensive haematuria were excluded. Healthy 125 individuals without history of SCD, diabetes mellitus, arterial hypertension, neoplastic, 126 127 cardiovascular, inflammatory, renal, lung and endocrine diseases were also eligible for the control 128 group.

129 Data collection

Important demographic and clinical history information about the participants were recorded using a well-structured questionnaire and patient case records. Animal protein consumption(fish,meat &egg) were categorised qualitatively as occurring rarely (one per month), irregularly (seven times per month), and regularly (twice per month). A wall-mounted ruler was used to measure height. A Zhongshan Camry Electronic Co. Ltd. bathroom scale (Guangdong, China) was used to assess weight. Estimates were made for height to the nearest centimetre without shoes and weight to the nearest 0.1 kg when wearing light clothes.

137 Sampling and analysis

Blood samples were collected following standard protocol (World Health Organization, 2010). Five
(5) millilitres (ml) (venous blood) were pulled from each participant and collected into K3 EDTA

tube, sodium citrate tube and Serum Separator tube (SST) – 1.8ml into sodium citrate tube first, 2.2
ml separated into SST second and 1ml into 4ml EDTA tube. Whole blood in EDTA was used for
Haemogram analysis. Serum in SST was used to analyze liver function markers, creatinine, urea,
electrolytes (sodium, potassium and chloride) and NGAL. Sodium citrate was used for fibrinogen
measurement. Participants were directed to collect a mid-stream urine in a cleaned dry urine
container. Mid-stream urine sample was used for UACR.

146 Laboratory assays

147 Participants' haemoglobin variants were confirmed by Hb electrophoresis. Full Blood Estimation 148 was done using five (5)- part Automated Haematology Analyser XN-550 (XN-550; Sysmex 149 Corporation, Kobe Japan). Kidney function tests (electrolytes, urea, and creatinine), liver function 150 tests (bilirubin, AST, ALT, ALP, GGT Total Protein and albumin), urine albumin-to-creatinine ratio were determined on Vitros 5600 integrated systems. Estimated GFR (eGFR) was calculated using 151 the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (2009) (eGFRcreat). 152 Normoalbuminuria and microalbuminuria were defined as urine microalbumin:creatinine ratio < 30 153 154 mg/g and > 30mg/g respectively. Fibrinogen was measured with Wonfo Fibrinogen reagent kit and OCG-102 Coagulation analyzer. Fibrinogen-to-Albumin ratio calculations involved dividing the 155 156 Fibrinogen (FIB) by serum Albumin (ALB) to arrive at values. A commercially available ELISA 157 kit (Melson Shanghai Chemical Ltd, China) was used for the sNGAL measurement. Reagent was used in accordance with the manufacturer's instructions to measure samples from the controls and 158 159 the participants using the solid phase ELISA technique. The commonly accepted reference value for serum NGAL is $5.68\pm1.34\mu$ g/L. 160

162 **Determination of sickle cell nephropathy**

The 2024 KDIGO classification (12) for establishing chronic kidney disease guidelines was used. Reduced eGFR and microalbuminuria were the main determinants of sickle cell nephropathy. For eGFR, nephropathy was classified as individual with reduced eGFR ($<60mL/min/1.73m^2$) and without nephropathy ($\geq 60mL/min/1.73m^2$). Estimated GFR (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (2009) (eGFRcreat) (13). Microalbuminuria was determined by urine albumin-to-creatinine ratio (UACR) greater than or

169 equal to 30mg/g and normoalbuminuria was defined as UACR less than 30 mg/g.

170 Statistical analysis

The study's data were entered and cleaned in Microsoft Excel (2016). The date were exported to R 171 programming version 4.2.3, and IBM Statistical Package for Social Sciences (version 26.0) for 172 173 analysis. Continuous variables were expressed as mean \pm standard deviation or median interguatile ranges depending on the normality while categorical variables were expressed as frequency and 174 percentages. The association of participants baseline parameters between the study groups was 175 176 investigated using the chi-square test. In addition, the post-hoc Bonferroni test and one-way ANOVA or Kruskal Wallis test followed by pairwise multiple comparisons were used to evaluate 177 the variations in continuous variable between study groups, depending on the normality. To examine 178 179 the relationship between sNGAL, eGFR, FAR, and UACR, Spearman's correlation was employed 180 and results represented as heatmaps. Using the Receiver Operator Characteristics Curve, the area under the curves for sNGAL, Urea, Creatinine and FAR for predicting sickle cell nephropathy were 181 182 determined. All computations of statistical significance were performed using a 95% confidence 183 interval and a *p*-value of 0.05.

184 **Results**

185 **Baseline characteristics of study participants**

186 A total of 104 patients (46 males and 58 females) with SCD were recruited. Seventy four (74) were 187 HbSS and thirty were (30) were HbSC. They were all in steady state based on their clinical status 188 assessed by haematologists. Fifty one (51) healthy individuals (13 males and 38 females) were 189 analysed. Following the 2024 KDIGO classification (12) for establishing chronic kidney disease 190 guidelines, 34(32.7%) out of the 104 SCD patients had microabuminuria. Subsequently, eleven (11) 191 out of the thirty-four (34) SCD participants with microalbuminuria (UACR≥30) had reduced eGFR 192 (<60mL/min/1.73m²), because microalbuminuria is the superior sensitive marker for kidney damage 193 as indicated in the KDIGO guidelines, 34(32.7%) of SCD participants were diagnosed with 194 nephropathy while 70(67.3%) were without nephropathy. Gender varied significantly across the groups (p=0.017) with 96(61.9%) being females and males being 59(38.1%). Again, the distribution 195 196 of age across the cases and controls was statistically significant (p=0.013) as majority of them were 197 less than 25 years 84(54.2%) and were more in the SCD non-nephropathy group 42(50.0%). The 198 participants' BMI varied significantly among the cases and controls (p < 0.0001) as majority were 199 having normal weights with least being obese 2(1.3%). Nearly all 152(98.1%) rarely smoked 200 tobacco and the difference across the groups was significant (p=0.044) and were rarely 139(89.7%) taking in alcohol (p=0.004). Although, there were no significant relation (p>0.05) across the groups 201 but larger proportion of the participants irregularly exercise 101(62.2%), and take in salt 97(62.6%), 202 203 regularly consume meat & fish 122(78.7%), and egg 126(81.3%) (Table 1).

204 Haemato-biochemical Profile of SCD nephropathy, SCD non-nephropathy and controls

Both diastolic and systolic blood pressures differed significantly across groups. Creatinine was elevated in the SCD nephropathy group (p=0.0320), compared to SCD non-nephropathy group.

207 Electrolyte levels such as sodium and potassium were significantly different across groups, with controls showing lower levels of sodium and potassium (p < 0.0001 and p = 0.0020, respectively). 208 AST, ALP, and total bilirubin were also significantly different across groups (p < 0.0001). Moreover, 209 210 hematological indices including RBC count, hematocrit, and hemoglobin were significantly lower 211 in the SCD nephropathy group (p < 0.0001), whilst inflammatory markers like WBC, neutrophil 212 count, and monocyte count were higher (p < 0.0001). Serum NGAL and eGFR levels also showed 213 significant differences, with SCD nephropathy patients having the highest sNGAL (p < 0.0001) and 214 the lowest eGFR (p=0.0250) (Table 2).

215 Correlation between sNGAL and biochemical parameters

There was a significant positive correlation between sNGAL and UACR, a significant negative correlation between UACR and eGFR. There was a weak but significant correlation between potassium and sNGAL (r=0.29, p<0.005), a significant moderate negative corelation between eGFR and urea (r= -0.50, p<0.0005) and a strong negative correlation with creatinine as it is already established (r=-0.90, p<0.0005). UACR also correlated weakly but significantly with creatinine in a direct proportion (r=0.27, p<0.005) (**Figure 1**).

Diagnostics performance of sNGAL, Creatinine, Urea and FAR in predicting nephropathy among SCD patients

224 Using the Receiver Operating Curve (ROC) analysis for predicting nephropathy among SCD

patients, sNGAL as a marker at a cutoff of >5.72 significantly predicted nephropathy among SCD

- patients with high Area under the Curve (AUC=0.742, p < 0.0001) and was very sensitive (91.2%)
- but less specific (51.4%). Also, Creatinine at a cutoff of >96.0 marginally predicted nephropathy
- among SCD patients significantly with AUC=0.618, p=0.048 however, it was less sensitive (47.1%)

but specific (81.4%). Urea and FAR predicted with an AUC=0.531 and AUC=0.462 respectively but were not statistically significant (p > 0.05) (**Table 3** and **Figure 2**).

231 **Discussion**

Renal involvement in SCD is demonstrated by the presence of crescent RBCs in the renal medulla, which cause ischemia, microinfarcts, reduced renal medullary blood flow, and renal papillary necrosis (14). Conventional renal markers remain normal until extensive renal damage hence the necessity for early diagnostic markers allows for implementation of preventive actions (15). This case-control study assessed NGAL and FAR as indicators for nephropathy among non-hospitalized SCD patients who were unaware of their renal status.

Most of the SCD patients were individuals with HbSS variant followed by HbSC variant which agrees with a research mastered by Ohene Frimpong *et al.*, (2008) and Ephraim *et al.*, (2015) from Ghana (16). Ko *et al.*, (2017) (17) reported that high protein intake can cause injury to the glomerular structure resulting in CKD which favors the high protein intake association with nephropathy in SCD subjects. However, restriction of protein intake is not recommended mainly due to the low energy state of SCD patients especially those with HbSS which may also explain the high protein intake in sickle cell nephropathy.

Prevalence of nephropathy among adult steady state SCD participants was 32.7% as indicated in 2024 KDIGO classification(12). This is above a prevalence of 17.1% nephropathy based on microalbuminuria found by Marouf et al., (2021) in Kuwait. However, this is below the prevalence indicated in a study by Ephraim *et al.*, (2015) that found that 68.4% of adult SCD patients had CKD based on reduced eGFR in Ghana. The variation in the prevalences might be due to the fact that eGFR only explore the function of the kidney whilst microalbuminuria determines kidney damage as indicated in KDIGO classification.

252 With respect to FBC parameters, there was lower haemoglobin and RBC levels in SCD 253 nephropathy (SCN) participants compared to controls and SCD non-nephropathy (Non-SCN) 254 participants. This confirms the significant association between haemoglobin, RBC and 255 hematocrit levels and kidney disease as already indicated by various studies(18-22). We also 256 reported significant diference between SCN, Non-SCN and healthy individuals with respect to 257 total WBC levels and differentials in a decreasing order which tells the story that SCD is an 258 inflammatory disease and get worse when there is an additional inflammatory disorder like 259 nephropathy which agrees with several studies (5, 23, 24). Also, in a prospective study 260 conducted by Aneke et al., (2014) in Nigeria reported high levels of platelets in SCD participants with CKD which is in agreement with this present study (25). The pattern of WBC 261 262 and platelets levels among participants justify the increase in inflammation in the SCN group 263 resulting in high levels of NGAL, FAR and renal parameters. With respect to LFT parameters, ALT which is very specific to liver was apparently normal and similar in participant groups 264 265 which rules out liver dysfunction in study participants. LFT markers seen in this study is in 266 accordance with a research done by Kotila et al., (2005) who observed minimal elevation of transaminases in steady state SCD patients (26). As far as the kidney biomarkers are concern, 267 268 this study reported markely increased levels of creatinine and urea which conforms to a research done by Ephraim et al., (2015) in Ghana. There was a minimal increased levels of potassium in 269 270 the SCN compared to the controls which agrees with findings from Alhwiesh et al., (2015). 271 NGAL was significantly higher in the SCN group as compared to the healthy controls. Marouf et al., (2020) and Atere et al., (2018) found increased levels of NGAL in steady state SCD pateints 272 273 and its relationship with renal abnormailities as comapred to healthy individuals which is

consistent with this present study. Fibrinogen-to-albumin ratio was significantly higher in the SCN

275 as comapared to Non-SCN and healthy controls(27). Increased fibrinogen and hypoalbuminuria 276 are biomarkers of inflammation, this was evident by a study conducted by Luyendyk et al., (2019) and Zhang et al., (2019), who also found their correlation with renal prognosis which agree with 277 278 this study. This study found a significant positive correlation between NGAL and UACR which is in line with a study performed by Marouf et al., (2021) who found a positive non-significant 279 280 correlation between plasma NGAL and UACR but a positive significant correlation between urine 281 NGAL and UACR. This observation could be attributed to the state of pateints in that they recruited both steady and VOC SCD and they were not grouped in the correlation analysis. There 282 283 was also a negative statistically significant correlation between eGFR and UACR. Also, there was 284 a significant strong negative correlation between eGFR and a mild significant negative relationship 285 existed between urea and eGFR. These observations are comparable to findings from (4, 5, 15, 28, 286 29). The optimal threshold at which NGAL level indicated impairment of the of kidney was 5.72ug/l with a sensitivity of 91.2% and specificity of 51.4%. Comaparing the Area under the 287 288 curves NGAL significantly performed better than the conventional markers (urea and creatinine) 289 with higher sensitivity (91.2%) than creatinine (47.1%) and that of urea (41.2%). However, 290 creatinine was highly specific but the AUC value was lower than that of NGAL, unlike urea that 291 had non-significant specificity and lower AUC value. This tells an interesting story that once there is kidney impairment in SCD individuals in steady state, NGAL would be able to detect it and can 292 293 be used as a predictive marker for nephropathy. These observations are comparable to a research 294 conducted by Atere et al., (2018) in Nigeria who comapared the AUC of NGAL and conventional markers (Urea and Creatinine) with NGAL having a superior AUC than urea and creatinine in both 295 296 steady and VOC states. However, Marouf and associates indicated that urine NGAL performs 297 better than plasma NGAL in predicting nephropathy in SCD in VOC state but could not find that

of SCD in steady state. Various studies have also compared NGAL levels in other non-SCD nephropathy studies indicating that NGAL was a better marker for nephropathy even in non-SCD patients which should be well looked at (29-32). Fibrinogen-to-albumin ratio performed poorly in the ROC analysis with a non-significant low sensitivity and specificity which indicates that FAR levels could not be used to predict nephropathy in SCD subjects as seen in a cancer study by Hwang *et al.*, (2017) which is inconsistent with this study, though FAR could be used to track nephropathy treatment due to the higher levels in SCD nephropathy group in this study.

Despite the novel findings, this study had limitations worth mentioning. The study recruited only 305 306 steady state SCD patients and thus not entirely a true reflection of all SCD adult patients. Also, 307 most of the SCD participants were young adults and may not be a reflective of old SCD patients. 308 Further studies should recruit both steady state and VOC state adult SCD patients with equal age 309 distribution. Urine albumin-to-creatinine ratio should be added to estimated glomerular filtration 310 rate as suggested by KDIGO to confirm chronic kidney disease and thus classify sickle cell 311 nephropathy. Further studies should be done to assess relationship between serum NGAL and 312 urine NGAL and how they predict sickle cell nephropathy.

313 **Conclusion**

In conclusion, this is the first attempt to investigate NGAL and FAR as indicators of nephropathy among adult steady state SCD patients in Ghana.The study demonstrated a higher NGAL and FAR levels among SCD with nephropathy as compared to apparently healthy individuals. The study demonstrated a significant correlation between Neutrophil Gelatinase- Associated Lipocalin and Albumin-to-Creatinine Ratio (UACR). Finally, NGAL as independent marker, is an early predictor of kidney disease as compared to urea and creatinine. Fibrinogen-to-albumin ratio can be used to track nephropathy treatment in

321 steady state sickle cell disease patients since it is elevated in those with sickle cell 322 nephropathy compared to healthy individuals.

323 Acknowledgements

- 324 We are grateful for the immense contributions of the staff of Komfo Anokye Teaching Hospital,
- 325 Suntreso Government Hospital and Kumasi South Hospital for their warm reception, not forgetting
- 326 our participants. Special thanks to the serology department of Komfo Anokye Teaching Hospital
- 327 on their support in storage of samples.

328 Authors' contributions

- 329 Conceptualization: Stephen Twumasi, Lilian Antwi Boateng, Enoch Odame Anto, Benedict
- 330 Sackey, Allwell Adofo Ayirebi
- 331 **Data curation**: Stephen Twumasi, Lesle Osei, Angela Opoku
- 332 Formal analysis: Stephen Twumasi, Richard Owusu Ansah, Godfred Yawson Scott, Alfred Effah
- 333 Investigation: Stephen Twumasi, Lilian Antwi Boateng, Enoch Odame Anto, Angela Opoku,
- 334 Leslie Osei, Vivian Paintsil, Joyce Duku, Emmanuel Asafo Adjei
- 335 Methodology : Stephen Twumasi, Lilian Antwi Boateng, Enoch Odame Anto
- 336 **Project administration**: Stephen Twumasi, Lilian Antwi Boateng, Enoch Odame Anto
- 337 **Resources:** Stephen Twumasi, Angela Opoku
- 338 Software: Stephen Twumasi, Richard Owusu Ansah, Godfred Yawson Scott, Alfred Effah
- 339 Supervision: Stephen Twumasi, Lilian Antwi Boateng, Christian Obirikorang, Enoch Odame
- 340 Anto
- 341 Validation: Stephen Twumasi, Lilian Antwi Boateng & Enoch Odame Anto
- 342 Visualization: Stephen Twumasi, Lilian Antwi Boateng & Enoch Odame Anto

- 343 Writing-original drtaft: Stephen Twumasi, Lilian Antwi Boateng, Enoch Odame Anto, Richard
- 344 Kobina Dadzie Ephraim, Christian Obirikorang, Benedict Sackey, Allwell Adofo Ayerebi
- 345 Writing-review & editing: Stephen Twumasi, Enoch Odame Anto, Benedict Sackey, Christian
- 346 Obirikorang, Alfred Effah, Richard Kobina Dadzie Ephraim, Allwell Adofo Ayirebi, Godfred
- 347 Yawson Scott, Richard Owusu Ansah, Angela Opoku, Leslie Osei, Vivian Paintsil, Joyce Duku,
- 348 Emmanuel Asafo Adjei, Lilian Antwi Boateng

349 **Funding**

350 The author(s) received no financial support for the research, authorship and or/ publication of this

351 article.

352 Availability of data

353 Data and materials for study are available upon request from the corresponding authors.

354 **Declarations**

The study was approved by the Committee on Human Research and Publication Ethics of the Kwame Nkrumah University of Science and Technology (CHRPE/AP/1037/23) and Komfo Anokye Teaching Hospital (KATH IRB/AP/175/23). Written consent of individual participants was sought after the aims, benefits, risk and right of withdrawal at any time from the study were well explained to the study participants in English and in the local dialect (mostly Twi) and their consent was obtained.

361 **Consent for publication**

362 Not applicable.

363 **Competing interests**

364 All authors declare that there is no competing interest.

365 **REFERENCES**

Voskaridou E, Terpos E, Michail S, Hantzi E, Anagnostopoulos A, Margeli A, et al.
 Early markers of renal dysfunction in patients with sickle cell/β-thalassemia. Kidney
 international. 2006;69(11):2037-42.

369 2. Saborio P, Scheinman JI. Sickle cell nephropathy. Journal of the American Society of
370 Nephrology. 1999;10(1):187-92.

371 3. Gurkan S, Scarponi KJ, Hotchkiss H, Savage B, Drachtman R. Lactate dehydrogenase as
a predictor of kidney involvement in patients with sickle cell anemia. Pediatric nephrology.
2010;25:2123-7.

Anto EO, Obirikorang C, Acheampong E, Adua E, Donkor S, Afranie BO, et al. Renal
abnormalities among children with sickle cell conditions in highly resource-limited setting in
Ghana. PloS one. 2019;14(11):e0225310.

5. Ephraim RKD, Osakunor DNM, Cudjoe O, Oduro EA, Asante-Asamani L, Mitchell J, et

al. Chronic kidney disease is common in sickle cell disease: a cross-sectional study in the Tema
Metropolis, Ghana. BMC nephrology. 2015;16:1-7.

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al. A more accurate
method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.
Annals of internal medicine. 1999;130(6):461-70.

Aygun B, Mortier NA, Smeltzer MP, Hankins JS, Ware RE. Glomerular hyperfiltration
 and albuminuria in children with sickle cell anemia. Pediatric nephrology. 2011;26:1285-90.

8. Sundaram N, Bennett M, Wilhelm J, Kim MO, Atweh G, Devarajan P, et al. Biomarkers for early detection of sickle nephropathy. American journal of hematology. 2011;86(7):559-66.

Sise ME, Barasch J, Devarajan P, Nickolas TL. Elevated urine neutrophil gelatinaseassociated lipocalin can diagnose acute kidney injury in patients with chronic kidney diseases.
Kidney international. 2009;75(1):115-6.

Audard V, Moutereau S, Vandemelebrouck G, Habibi A, Khellaf M, Grimbert P, et al.
First evidence of subclinical renal tubular injury during sickle-cell crisis. Orphanet Journal of
Rare Diseases. 2014;9:1-4.

Hwang K-T, Chung JK, Roh EY, Kim J, Oh S, Kim YA, et al. Prognostic influence of
 preoperative fibrinogen to albumin ratio for breast cancer. Journal of breast cancer.

395 2017;20(3):254-63.

396 12. KDIGO-CKD. WG. KDIGO 2024 Clinical Practice Guideline for the Evaluation and 397 Management of Chronic Kidney Disease Kidney Int 2024:105(4S): S117 S314

Management of Chronic Kidney Disease. Kidney Int 2024;105(4S): S117–S314.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A
 new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.

400 14. Alhwiesh A. An update on sickle cell nephropathy. Saudi Journal of Kidney Diseases and

401 Transplantation. 2014;25(2):249-65.

402 15. Marouf R, Adekile AD, El-Muzaini H, Abdulla R, Mojiminiyi OA. Neutrophil

gelatinase–associated lipocalin as a biomarker of nephropathy in sickle cell disease. Annals of
 Hematology. 2021;100:1401-9.

405 16. Ohene-Frempong K, Oduro J, Tetteh H, Nkrumah F. Screening newborns for sickle cell
406 disease in Ghana. Pediatrics. 2008;121(Supplement_2):S120-S1.

407 17. Ko GJ, Obi Y, Tortorici AR, Kalantar-Zadeh K. Dietary protein intake and chronic

408 kidney disease. Current Opinion in Clinical Nutrition & Metabolic Care. 2017;20(1):77-85.

- 409 18. de Francisco AL, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in
- 410 chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT plus.
 411 2009;2(suppl 1):i18-i26.
- 412 19. Drücke TB, Locatelli F, Clyne N, Eckardt K-U, Macdougall IC, Tsakiris D, et al.
- 413 Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New
- 414 England Journal of Medicine. 2006;355(20):2071-84.
- 415 20. Duncan JA, Levin A. Sex, haemoglobin and kidney disease: new perspectives. European 416 journal of clinical investigation. 2005;35:52-7.
- 417 21. Saraf SL, Zhang X, Kanias T, Lash JP, Molokie RE, Oza B, et al. Haemoglobinuria is
- associated with chronic kidney disease and its progression in patients with sickle cell anaemia.
 British journal of haematology. 2014;164(5):729-39.
- 420 22. Strippoli GF, Navaneethan SD, Craig JC, Palmer SC. Haemoglobin and haematocrit
- 421 targets for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews.
 422 2006(4).
- Drawz P, Ayyappan S, Nouraie M, Saraf S, Gordeuk V, Hostetter T, et al. Kidney disease
 among patients with sickle cell disease, hemoglobin SS and SC. Clinical Journal of the American
 Society of Nephrology. 2016;11(2):207-15.
- 426 24. Okpala I. The intriguing contribution of white blood cells to sickle cell disease–a red cell 427 disorder. Blood reviews. 2004;18(1):65-73.
- 428 25. Aneke JC, Adegoke A, Oyekunle A, Osho P, Sanusi A, Okocha E, et al. Haematological
- and clinical profile in Nigerian sickle cell disease patients with and without chronic kidney
 disease. Orient Journal of Medicine. 2014;26(3-4):88-93.
- 431 26. Kotila T, Adedapo K, Adedapo A, Oluwasola O, Fakunle E, Brown B. Liver dysfunction
 432 in steady state sickle cell disease. Annals of hepatology. 2005;4(4):261-3.
- 433 27. Hariri E, Mansour A, El Alam A, Daaboul Y, Korjian S, Aoun Bahous S. Sickle cell
- 434 nephropathy: an update on pathophysiology, diagnosis, and treatment. International Urology and
 435 Nephrology. 2018;50:1075-83.
- 436 28. Atere A, Ajani O, Akinbo D, Adeosun O, Anombem O. Serum levels of neutrophil
- gelatinase-associated lipocalin (NGAL) as predictor of acute kidney injury in sickle cell subjects.
 J Biomed Sci. 2018;7(4):17.
- 439 29. Danquah M, Owiredu WK, Jnr BE, Serwaa D, Odame Anto E, Peprah MO, et al.
- 440 Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) as an early biomarker for
- 441 detection of renal failure in hypertensives: a case–control study in a regional hospital in Ghana.
- 442 BMC nephrology. 2023;24(1):114.
- 443 30. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, et al.
- 444 Neutrophil gelatinase–associated lipocalin (NGAL) as a marker of kidney damage. American
 445 journal of kidney diseases. 2008;52(3):595-605.
- 446 31. Liu H, Wan X, Shi Y, Huang F, Shu H, Huang R, et al. Neutrophil gelatinase-associated
- lipocalin contributes to increased risk of cardiovascular death after acute coronary syndrome.
 International Journal of General Medicine. 2021:4887-95.
- 449 32. Prashant P, Dahiya K, Bansal A, Vashist S, Dokwal S, Prakash G. Neutrophil Gelatinase-
- 450 Associated Lipocalin (NGAL) as a potential early biomarker for diabetic nephropathy: a meta-
- 451 analysis. International Journal of Biochemistry and Molecular Biology. 2024;15(1):1.
- 452
- 453

454 Table 1: Baseline characteristics of study participants

			Cases=10	4(67.1%)	
		-	SCD non-	SCD	_
	Total	Control	nephropathy	Nephropathy	
Variables	N=155	n=51	n=70	n=34	<i>p</i> -value
Age Group (years)					0.013
<25	84(54.2)	18(31.4	42(50.0)	24(28.6)	
25-34	38(24.5)	14(36.8)	16(42.1)	8(21.1)	
35-44	19(12.3)	11(57.9)	7(36.8)	1(5.3)	
>44	14(9.0)	8(57.1)	5(35.7)	1(7.1)	
Gender	~ /				0.017
Male	59(38.1)	13(22.0)	35(59.3)	11(18.6)	
Female	96(61.9)	38(39.6)	35(36.5)	23(24.0)	
BMI					<0.0001
Underweight	9(5.8)	0(0.0)	4(44.4)	5(55.6)	
Normal	101(65.2)	23(22.8)	55(54.5)	23(22.8)	
Overweight	43(27.7)	28(65.1)	9(20.9)	6(14.0)	
Obese	2(1.3)	0(0.0)	2(100.0)	0(0.0)	
SCD Phenotype					0.819*
HbSC	30(28.8)	-	21(70.0)	9(30.0)	
HbSS	74(71.2)	-	49(66.2)	25(33.8)	
Vigorous Exercise			· · · ·	()	0.784
Regular	46(29.7)	16(34.8)	22(47.8)	8(17.4)	
Irregular	101(65.2)	33(32.7)	45(44.6)	23(22.8)	
Rarely	8(5.2)	2(25.0)	3(37.5)	3(37.5)	
Meat&Fish	~ /			()	
Consumption					0.508
Regular	122(78.7)	38(31.1)	59(48.4)	25(20.5)	
Irregular	31(20.0)	12(38.7)	10(32.3)	9(29.0)	
Rarely	2(1.3)	1(50.0)	1(50.0)	0(0.0)	
Egg Consumption					0.056
Regular	126(81.3)	36(28.6)	61(48.4)	29(23.0)	
Irregular	29(18.7)	15(51.7)	9(31.0)	5(17.2)	
Tobacco Smoking					0.044
Irregular	3(1.9)	3(100.0)	0(0.0)	0(0.0)	
Rarely	152(98.1)	48(31.6)	70(46.1)	34(22.4)	
Alcohol Intake					0.004
Regular	2(1.3)	2(100.0)	0(0.0)	0(0.0)	
Irregular	14(9.0)	10(71.4)	2(14.3)	2(14.3)	
Rarely	139(89.7)	39(28.1)	68(48.9)	32(23.0)	

Salt Intake				С).066
Regular	47(30.3)	14(29.8)	21(44.7)	12(25.5)	
Irregular	97(62.6)	29(29.9)	47(48.5)	21(21.6)	
Rarely	11(7.1)	8(72.7%)	2(18.2)	1(9.1)	

455 BMI: Body Mass Index, HbSS; Haemoglobin SS, HbSC; Haemoglobin SC, Data presented as frequency (%). Chi-

456 square *p*-values were presented, p < 0.05 was considered statistically significant. Bolded *p*-value was statistically

457 significant, * ; Fisher Exact test computed for the cases only

 Table 2: Haemato-biochemical Profile of SCD patients nephropathy, SCD non-nephropathy and controls

	SCD non-nephropathy	SCD Nephropathy	Controls	
Variable	(n = 70)	n = (34)	(n = 51)	<i>p</i> -value
Diastolic Blood Pressure (mm Hg)	71.00 (67.00 - 76.00)	71.50 (64.75 - 76.50)	76.00 (74.00 - 79.00)	<0.0001 ^{b,c}
Systolic Blood Pressure (mm Hg)	119.00 (112.00 - 121.25)	119.00 (112.00 - 127.00)	112.00 (109.00 - 119.00)	<0.0001 ^{b,c}
Urea (mmol/L)	2.10 (1.58 - 2.87)	2.19 (1.31 - 5.05)	2.60 (1.63 - 3.03)	0.7890
Creatinine (mmol/L)	53.50 (44.00 - 76.25)	72.00 (47.00 - 156.00)	68.00 (52.00 - 77.00)	0.0320 ^a
BUN/Creatinine ratio	18.15 (13.48 - 24.90)	17.35 (13.55 - 23.05)	16.40 (12.50 - 21.10)	0.2300
Sodium (mmol/L)	142.00 (141.00 - 144.00)	143.00 (140.75 - 145.00)	140.00 (139.00 - 142.00)	<0.0001 ^{b,c}
Potassium (mmol/L)	4.60 (4.50 - 5.00)	4.90 (4.60 - 5.20)	4.40 (4.00 - 4.80)	0.0020 ^c
Chlorine (mmol/L)	106.00 (102.00 - 109.00)	107.00 (102.00 - 110.00)	104.00 (103.00 - 107.00)	0.2780
Aspartate Transaminase (U/L)	47.55 (37.38 - 59.13)	50.75 (38.90 - 70.25)	32.00 (28.40 - 38.90)	<0.0001 ^{b,c}
Alanine Transaminase (U/L)	23.90 (20.83 - 32.35)	25.20 (19.65 - 28.65)	24.80 (17.60 - 31.40)	0.8070
Alkaline Phosphatase (U/L)	103.05 (77.83 - 135.55)	99.20 (71.63 - 166.33)	72.10 (59.40 - 94.30)	<0.0001 ^{b,c}
GGT (U/L)	41.50 (24.88 - 56.53)	36.15 (24.55 - 53.25)	26.80 (22.70 - 40.50)	0.0140^b
Albumin (g/L)	41.80 (39.88 - 43.80)	41.60 (38.55 - 44.05)	42.20 (39.30 - 44.60)	0.4500
Total Bilirubin (mmol/L)	27.00 (15.78 - 38.88)	29.55 (15.38 - 41.65)	6.10 (4.10 - 11.30)	<0.0001 ^{b,c}
Direct Bilirubin (mmol/L)	1.40 (0.00 - 5.10)	2.65 (0.00 - 5.90)	1.80 (0.90 - 3.00)	0.4970
Indirect Bilirubin (mmol/L)	24.25 (13.50 - 35.05)	24.25 (13.93 - 39.33)	4.10 (3.10 - 8.10)	<0.0001 ^{b,c}
Fibrinogen (g/L)	4.31 (3.39 - 5.17)	4.35 (2.71 - 5.12)	2.40 (2.01 - 3.24)	<0.0001 ^{b,c}
FAR	0.10 (0.08 - 0.12)	0.11 (0.07 - 0.12)	0.06 (0.05 - 0.08)	<0.0001 ^{b,c}
RBC ($10^{6}/mL$)	3.08 (2.52 - 3.94)	2.73 (2.43 - 3.47)	4.42 (3.96 - 4.85)	<0.0001 ^{b,c}
Hematocrit (%)	25.75 (22.90 - 29.68)	24.50 (21.75 - 30.13)	35.60 (31.90 - 39.50)	<0.0001 ^{b,c}
MCV (fL)	85.80 (74.75 - 96.50)	88.30 (78.00 - 94.78)	81.40 (76.40 - 85.10)	0.0170 ^{b,c}
MCH (pg)	29.55 (25.98 - 32.78)	30.30 (27.25 - 32.85)	27.70 (25.00 - 29.20)	0.0020 ^{b,c}
MCHC(g/dL)	35.35 (32.75 - 36.60)	34.70 (32.85 - 36.03)	33.90 (32.60 - 34.70)	0.0060 ^b
RDW-SD (fL)	59.00 (46.85 - 66.30)	61.90 (50.98 - 71.53)	40.10 (38.20 - 42.80)	<0.0001 ^{b,c}
RDW-CV (%)	19.20 (17.08 - 22.73)	19.80 (17.50 - 25.35)	13.80 (12.90 - 14.60)	<0.0001 ^{b,c}
PLT $(10^{3}/mL)$	279.00 (171.75 - 375.50)	325.00 (214.25 - 455.25)	248.00 (205.00 - 292.00)	0.0490 ^c
PDW (fL)	11.80 (9.90 - 13.50)	12.45 (10.48 - 14.73)	12.40 (11.40 - 13.70)	0.2510
MPV (fL)	10.50 (9.48 - 11.50)	11.00 (10.00 - 11.98)	10.90 (10.40 - 11.40)	0.1860
PCT (%)	0.30 (0.20 - 0.40)	0.36 (0.23 - 0.51)	0.27 (0.24 - 0.33)	0.0550

WBC $(10^{3}/mL)$	8.38 (6.03 - 10.97)	8.91 (7.70 - 9.85)	5.57 (4.90 - 6.85)	<0.0001 ^{b,c}
Lymphocyte Count (10 ³ /mL)	3.37 (2.47 - 4.21)	3.44 (2.89 - 3.89)	2.18 (1.87 - 2.63)	<0.0001 ^{b,c}
Monocyte Count $(10^3 / \text{mL})$	0.68 (0.46 - 0.99)	0.72 (0.46 - 0.93)	0.53 (0.43 - 0.63)	0.0050 ^{b,c}
Neutrophil Count (10 ³ /mL)	3.46 (2.65 - 5.35)	4.25 (3.32 - 5.23)	2.82 (1.93 - 3.60)	<0.0001 ^{b,c}
Eosinophil Count (10 ³ /mL)	0.13 (0.07 - 0.26)	0.15 (0.10 - 0.25)	0.10 (0.05 - 0.16)	0.0140 ^{b,c}
Basophil Count (10 ³ /mL)	0.06 (0.03 - 0.10)	0.06 (0.04 - 0.09)	0.03 (0.02 - 0.04)	<0.0001 ^{b,c}
Neutrophil to Lymphocyte Ratio	1.14 (0.82 - 1.61)	1.15 (1.03 - 1.56)	1.25 (0.95 - 1.68)	0.6270
$IG\# (10^{3}/mL)$	0.06 (0.03 - 0.09)	0.05 (0.03 - 0.11)	0.01 (0.01 - 0.02)	<0.0001 ^{b,c}
Nucleated RBC $(10^3/mL)$	0.05 (0.02 - 0.11)	0.07 (0.04 - 0.25)	0.00 (0.00 - 0.01)	<0.0001 ^{b,c}
Reticulocyte Count (10 ⁶ /mL)	0.15 (0.12 - 0.22)	0.17 (0.12 - 0.27)	0.04 (0.02 - 0.05)	<0.0001 ^{b,c}
Total Protein (g/L)	87.38 (83.05 - 92.66)	87.96 (81.49 - 95.05)	78.28 (72.75 - 85.01)	<0.0001 ^{b,c}
Globulin (g/L)	45.50 (42.20 - 50.48)	45.40 (41.08 - 54.40)	36.40 (32.30 - 40.10)	<0.0001 ^{b,c}
Hemoglobin (g/dL)	9.00 (8.00 - 10.40)	8.65 (7.55 - 9.80)	11.90 (10.80 - 13.20)	<0.0001 ^{b,c}
Platelet to Lymphocyte Ratio	78.38 (56.40 - 115.50)	104.79 (68.17 - 141.26)	116.35 (85.22 - 151.41)	<0.0001 ^{b,c}
sNGAL (µg/L)	5.72 (4.76 - 6.52)	6.64 (6.23 - 7.29)	4.47 (3.95 - 4.87)	<0.0001 ^{a,b,c}
eGFR (mL/min/1.73m ²)	139.07 (96.97 - 183.09)	95.73 (47.80 - 166.43)	120.66 (106.23 - 155.49)	0.0250 ^a

461BUN-Blood Urea Nitrogen, WBC- White Cell Count, RBC- Red Blood Count, MCV-Mean Cell Volume, MCH- Mean Cell Haemoglobin, MCHC- Mean Cell462Haemoglobin Concentration, PLT- Platelet Count, PDW- Platelet Distribution Width, MPV-Mean Platelet Volume, P-LCR- Platelet- Large Cell Ratio, PCT-463Plateletcrit, eGFR-Estimated Glomerular Filtration Rate. a: significant when SCD non-nephropathy is compared to SCD nephropathy, b: significant when SCD464non-nephropathy is compared to Control, c: significant when SCD nephropathy is compared to Control. Kruskal Wallis p-values were presented, p < 0.05 and465bolded means statistically significant

	op nop n		,					
Marker	Cut-off	Sensitivity (95% CI)	Specificity (95% CI)	PPV	NPV	LR+	LR-	p-value
sNGAL	>5.72	91.2 (76.1-97.6)	51.4(40.0-62.7)	47.7	92.3	1.88	0.17	<0.0001
Creat	>96.0	47.1(31.5-63.2)	81.4(70.6-88.9)	55.2	76.0	2.534	0.65	0.048
Urea	>3.06	41.2(26.4-57.8)	80.0(69.0-87.8)	50	73.7	2.059	0.735	0.649
FAR	>0.12	26.5(14.5-43.4)	80.0(69.0-87.8)	39.1	69.1	1.324	0.919	0.536

466	Table 3: Diagnostic performance of sNGAL, Creatinine, Urea, and FAR, in predicting
467	Nephropathy among SCD patients


468 Abbreviations: FAR; Fibrinogen-Albumin Ratio, Crea: Creatinine, sNGAL: serum Neutrophil

469 Gelatinase – Associated Lipocalin, CI: Confidence interval, PPV: Positive predictive value, NPV:

470 Negative predictive value, LR+: Positive likelihood ratio, LR-: Negative likelihood ratio

	sNGAL	eGFR	UACR	urea	creatinine	Sodium	Potassium	Chlorine		1 .0
sNGAL	1.00	0.06	0.28	-0.14	-0.03	-0.06	0.29	-0.01		1.0
eGFR	0.06	1.00	-0.34	-0.50	-0.90	-0.06	-0.11	-0.08		- 0.5
UACR	** 0.28	*** -0.34	1.00	0.07	0.27	0.12	0.14	0.04		
urea	-0.14	*** -0.50	0.07	1.00	0.56	0.19	0.04	0.06		- 0
creatinine	-0.03	*** -0.90	** 0.27	*** 0.56	1.00	0.06	0.07	0.05] []
Sodium	-0.06	-0.06	0.12	0.19	0.06	1.00	0.02	0.49		0.5
Potassium	** 0.29	-0.11	0.14	0.04	0.07	0.02	1.00	0.22		-0.5
Chlorine	-0.01	-0.08	0.04	0.06	0.05	*** 0.49	* 0.22	1.00		-1.0

474Figure 1: Heat map representing the correlation matrix between sNGAL, eGFR, UACR and the Renal475function Tests (RFT); * Indicates the significance level of p < 0.05 of the correlation, **=p < 0.005 and ***=p < 0.0005.476sNGAL; Neutrophil Gelatinase Associated Lipocalin eGFR; Estimated Glomerular Filtration Rate, UACR; Urine477Albumin-to-creatinine ratio.





488